Abstract Library

#4495 Clinicopathologic characteristics and prognostic analysis of rectal neuroendocrine tumours: A multicentre clinical study

Introduction: The incidence of rectal neuroendocrine tumours (R-NETs) has increased significantly in recent years.

Conference:

Presenting Author: Lian J

Authors: Lian J, Xing W, Lu H,

Keywords: Rectal Neuroendocrine Tumour, clinical data, real-world, CgA, progression-free survival,

#4485 Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms (NEN) treated with [177Lu]Lu-DOTA-Octreotate (LuTate) therapy over a 4.5 year period at a single high volume treatment centre

Introduction: LuTate therapy is an effective treatment for patients with somatostatin receptor expressing NEN. However, patients (pts) with functional tumours may develop an acute flare of symptoms during or after PRRT.

Conference:

Presenting Author: Kong G

Authors: Neeson L, Boehm E, Chiang C, Michael M, Sachithanandan N,

Keywords: PRRT, NET, high-risk, flare, outcomes, NEN, single centre,

#4408 Metabolic syndrome (MetS) and metastatic disease in patients with sporadic small intestine neuroendocrine tumour (SiNET)

Introduction: Small intestine neuroendocrine tumours (SiNETs) are rare neoplasms in which the identification of new risk factors is essential. Metabolic syndrome (MetS) is a cluster of risk factors that lead to increased mortality, especially by cardiovascular (CV) causes. MetS diagnosis is obtained with International Diabetes Federation (IDF) 2005 criteria.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: small intestine neuroendocrine tumour, metabolic syndrome, metastatic disease, survival, progression, metastasis,

#4335 Late nephrotoxicity of peptide receptor radionuclide therapy (PRRT) and impact of selected factors – A single centre cohort study

Introduction: The most common side effect of radioligand therapy is renal damage, early or late. However, limited data exist for the long-term side effects and impact of additional risk factors on renal function in patients treated with PRRT.

Conference:

Presenting Author: Sygula A

Authors: Sygula A, Kropinska A, Kotecka-Blicharz A, Gawlik T, Wycislik M,

Keywords: Neuroendocrine tumour, PRRT, nephrotoxicity, yttrium-90, lutetium-177,

#4331 Amino acid-induced hyperkalaemia during peptide receptor radionuclide therapy (PRRT): A case report and literature review

Introduction: PRRT an established treatment for neuroendocrine tumours (NETs). Therapy requires prophylactic positively charged amino acid (AA) co-infusion to reduce renal radiation exposure. AA infusion has been associated with metabolic acidosis and electrolyte abnormalities, particularly hyperkalaemia; comprehensive data on the prevalence and severity of these complications remains limited.

Conference:

Presenting Author:

Authors: Osher E, Wolf I, Geva R, Sofer Y, Greenman Y,

Keywords: PRRT, hyperkalaemia, amino acid infusion, neuroendocrine tumour, adverse effects,